Ylihonko K, Hakala J, Niemi J, Lundell J, Mäntsälä P
Department of Biochemistry and Food Chemistry, University of Turku, Finland.
Microbiology (Reading). 1994 Jun;140 ( Pt 6):1359-65. doi: 10.1099/00221287-140-6-1359.
Twelve mutants of Streptomyces galilaeus (ATCC 31615) blocked in the production of aclacinomycin A, an anthracycline antibiotic with significant antitumour activity, accumulated intermediates of the biosynthesis of aclacinomycins and several anthracyclines with variant sugar moieties. Three of these aklavinone glycosides have not been described before. Mutant strains H028, H061 and H036 were blocked before the formation of aklavinone, a common intermediate for most anthracyclines. Strain H039 accumulated aklavinone and H026, H035, H038 and H054 had mutations that changed glycosylation of aklavinone. Characterization of the mutants and their products is described.
加利利链霉菌(ATCC 31615)的12个突变体在产生阿克拉霉素A(一种具有显著抗肿瘤活性的蒽环类抗生素)的过程中受阻,积累了阿克拉霉素生物合成的中间体以及几种具有不同糖基部分的蒽环类化合物。其中三种阿克拉维酮糖苷此前未曾有过描述。突变菌株H028、H061和H036在阿克拉维酮(大多数蒽环类化合物的常见中间体)形成之前受阻。菌株H039积累了阿克拉维酮,而H026、H035、H038和H054发生了改变阿克拉维酮糖基化的突变。本文描述了这些突变体及其产物的特征。